# Stem Cell Educator Therapy in Diabetes

Study · id `cardio:ct-nct03390231` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03390231](<https://clinicaltrials.gov/study/NCT03390231>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03390231

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 100 participants.

## Technical summary

Registry record NCT03390231. Allocation not applicable; no masking; primary purpose treatment. Start 2017-11-27 (actual); primary completion 2020-12-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 100 participants (planned count; ClinicalTrials.gov record NCT03390231, source copy `cardio:ctgov-nct03390231-2019-02-05`, retrieved 2026-10-26)
- Started: 2017-11-27 (actual) (ClinicalTrials.gov record NCT03390231, source copy `cardio:ctgov-nct03390231-2019-02-05`, retrieved 2026-10-26)
- Primary completion: 2020-12-30 (anticipated) (ClinicalTrials.gov record NCT03390231, source copy `cardio:ctgov-nct03390231-2019-02-05`, retrieved 2026-10-26)
- Completion: 2020-12-31 (anticipated) (ClinicalTrials.gov record NCT03390231, source copy `cardio:ctgov-nct03390231-2019-02-05`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT03390231, source copy `cardio:ctgov-nct03390231-2019-02-05`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03390231-2019-02-05`, retrieved 2026-10-26)

## The registry's words

- Brief title: Stem Cell Educator Therapy in Diabetes
- Condition: Diabetes Mellitus, Type 1
- Condition: Diabetes Mellitus, Type 2
- Intervention (Combination product): Stem Cell Educator therapy
- Lead sponsor: Throne Biotechnologies Inc.
- Lead sponsor class: INDUSTRY
- Collaborator: Chinese PLA General Hospital
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as a collaborator: Chinese PLA General Hospital (`cardio:org-chinese-pla-general-hospital`)

## Provenance

Content hash: e82d496bb6da85e6852b5b83219161f0470fc9d501156413b8198550c34791c6
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
